AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Efficacy and Safety of Second Generation Cholesteryl Ester Transfer Protein Inhibitors in Patients with Heterozygous Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
By Gadelmawla AF, Mohamed AE, Abomohsen M et al.
Introduction: Heterozygous familial hypercholesterolemia (HeFH) is a common inherited lipid disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular risk. Second-generation cholesteryl ester transfer protein (CETP) inhibitors may provide additional lipid-lowering benefit when added to background lipid-lowering therapy. We evaluated the efficacy and safety of second-generation CETP inhibitors versus placebo in adults with HeFH receiving stable lipid-lowering therapy. Methods: PubMed, EMBASE, Cochrane Library, Scopus, and Web of Science were searched from inception to May 10, 2026, for randomized controlled trials comparing second-generation CETP inhibitors with placebo in adults with HeFH. The primary outcome was change in LDL-C. Secondary outcomes included LDL-C goal attainment, non-HDL-C, apolipoprotein B, lipoprotein(a), HDL-C, apolipoprotein A1, triglycerides, and adverse events. Random-effects meta-analysis was performed using R software. Results: Three randomized controlled trials including 728 participants were included. Compared with placebo, CETP inhibitors significantly reduced LDL-C (MD -43.38 mg/dL, 95% CI -52.85 to -33.91; P<0.001; Figure A ), non-HDL-C (MD -48.77 mg/dL, 95% CI -60.46 to -37.09), apolipoprotein B (MD -23.45 mg/dL, 95% CI -32.59 to -14.30), and lipoprotein(a) (MD -34.92 nmol/L, 95% CI -57.48 to -12.35). CETP inhibitors also increased HDL-C and apolipoprotein A1. Patients receiving CETP inhibitors were more likely to achieve LDL-C <100 mg/dL (RR 2.56, 95% CI 1.45 to 4.53; P=0.001) and LDL-C <70 mg/dL (RR 5.65, 95% CI 2.75 to 11.58; P<0.001; Figure B ). No significant difference was observed for triglycerides or overall adverse events. Heterogeneity was moderate to high for several lipid outcomes. Conclusion: Second-generation CETP inhibitors significantly improve LDL-C and multiple atherogenic lipid parameters in adults with HeFH receiving background lipid-lowering therapy. They also increase the likelihood of achieving clinically relevant LDL-C targets without an obvious short- to medium-term safety signal. Larger and longer-term randomized trials are needed to confirm cardiovascular outcome benefit and long-term safety.